Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research

Gooren, Louis; Behre, Hermann M.; Saad, Farid; Frank, Annika; Schwerdt, Sebastian

doi:10.1080/13685530701600885

Cited by 55 publications

(43 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 Recent consensus recommendations and guidelines for TDS diagnosis and management are available; 1,4 yet, less than 10% of affected individuals receive T therapy, 7 suggesting underutilization of these guidelines. Barriers to proper diagnosis and management may include: (1) a lack of physician awareness on associated diseases (such as MetS, diabetes and cardiovascular disease) and the ability of testosterone replacement therapy (TRT) to reduce disease symptoms, [8][9][10][11] (2) unfounded concerns about prostate health 4,12 and (3) insufficient dissemination of the guidelines in Canada. To reduce these barriers a multidisciplinary panel convened with the goal of improving TDS knowledge transfer to Canadian physicians.…”

Section: Introductionmentioning

confidence: 99%

A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians

Morales

Bella

Chun

et al. 2013

CUAJ

View full text Add to dashboard Cite

The percentage of men receiving appropriate management for testosterone deficiency syndrome (TDS) is small in comparison to prevalence estimates. This is despite linkages to cardiovascular disease, osteoporosis, diabetes, sexual function, sarcopenia, emotional well-being and the metabolic syndrome. Furthermore, the availability of guidelines has not significantly enhanced the care of TDS patients. A multidisciplinary group of medical experts sought to improve the management of testosterone-deficient patients by Canadian physicians. This report describes their conclusions and defines an algorithm for appropriate TDS management. RésuméLe pourcentage d'hommes recevant une prise en charge appropriée pour un syndrome de carence en testostérone est faible en comparaison avec les taux de prévalence évalués, et ce, malgré le lien entre ce syndrome et les maladies cardiovasculaires, l'ostéoporose, le diabète, la fonction sexuelle, la sarcopénie, le bien-être émo-tionnel et le syndrome métabolique. Par ailleurs, la publication de guides de pratique n'a pas amélioré de façon significative les soins offerts aux patients atteints du syndrome de carence en testostérone. Une équipe multidisciplinaire de médecins a tenté d'améliorer la prise en charge des patients atteints de ce syndrome par les médecins canadiens. Le présent rapport décrit leurs conclusions et propose un algorithme de prise en charge.

show abstract

Section: Introductionmentioning

confidence: 99%

A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians

Morales

Bella

Chun

et al. 2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…Testosterone deficiency profoundly impairs male health resulting in increased morbidity and decreased quality of life. 27 The physiopathology of low testosterone levels in type 2 diabetics is not well defined. It might be a result of insulin resistance (the characteristic feature of type 2 diabetes) which may result in part an alteration in Leydig cell function.…”

Section: Discussionmentioning

confidence: 99%

Association between androgen deficiency and metabolic syndrome in men with type 2 diabetes mellitus

Mohieldein¹,

Alzohairy²,

Hasan³

2014

Int Jour of Biomed Res

View full text Add to dashboard Cite

“…1 Controversy continues, however, on the impact of TRT and its effect on the prostate. While the effects of TRT on benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) are as yet unsettled, the role of TRT in prostate cancer appears to be clearer.…”

Section: Wwwtrendsinmenshealthcom Trends In Urology and Men's Health mentioning

confidence: 99%

Prostate cancer and testosterone replacement therapy: what is the risk?

Carson¹,

Kirby

2017

Trends Urology & Men Health

View full text Add to dashboard Cite

T he last decade has seen a rise in testosterone replacement therapy (TRT) internationally.1 Controversy continues, however, on the impact of TRT and its effect on the prostate. While the effects of TRT on benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) are as yet unsettled, the role of TRT in prostate cancer appears to be clearer.The effects of testosterone and castration on the prostate and prostate cancer have a long history, with the sentinel publication of Charles Huggins and Clarence V. Hodges in 1941 as the first clear demonstration of the effects of withdrawing testosterone by castration or oestrogen on the progression of prostate cancer. 2 In that publication, the authors also showed that, in a single patient, withdrawal of testosterone by castration and subsequent replacement of testosterone had the deleterious effect of causing the prostate cancer to first involute then regrow. This publication and subsequent reviews and presentations led to the conventional wisdom that testosterone could cause prostate cancer, and that TRT could either induce de novo prostate cancer or unearth an occult prostate malignancy.

show abstract

Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research

Abstract: World-wide physicians require more education on diagnosing T deficiency, on the role of T in erectile dysfunction and the relative safety of testosterone treatment.

Cited by 55 publications

References 22 publications

A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians

A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians

Association between androgen deficiency and metabolic syndrome in men with type 2 diabetes mellitus

Prostate cancer and testosterone replacement therapy: what is the risk?

Contact Info

Product

Resources

About